4.1 Article

Treatment and Prevention of Rotavirus Infection in Children

期刊

CURRENT INFECTIOUS DISEASE REPORTS
卷 15, 期 3, 页码 -

出版社

SPRINGER
DOI: 10.1007/s11908-013-0333-5

关键词

Rotavirus; Rotavirus vaccine; Rotavirus gastroenteritis; Rotavirus surveillance

资金

  1. Merck and Company
  2. Merck
  3. GlaxoSmithKline Biologicals
  4. GlaxoSmithKline

向作者/读者索取更多资源

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on child-hood morbidity and mortality. No antiviral therapy is available. Treatment of rotavirus gastroenteritis is limited to rehydration therapy. Recently, therapies, such as probiotics, have been developed as adjuncts to rehydration therapy. Two effective rotavirus vaccines are available and recommended for routine immunization of all infants. These vaccines have been introduced in both developed and developing countries. As rotavirus vaccines are implemented, studies that assess health impact, indirect benefits, and strain changes after the introduction of rotavirus vaccine have been reported. In the United States, rotavirus vaccination has led to dramatic drops in severe rotavirus-related hospitalizations and has reduced emergency room visits. Herd immunity has also been noted after routine rotavirus immunization. There have been no significant strain shifts or escape mutants noted since the introduction of rotavirus vaccines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据